Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Buenos Aires - Delayed Quote ARS

Merck & Co., Inc. (MRK.BA)

Compare
22,375.00
+425.00
+(1.94%)
At close: February 28 at 4:59:07 PM GMT-3
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
64,168,000
64,168,000
60,115,000
59,283,000
48,704,000
Cost of Revenue
15,193,000
15,193,000
16,126,000
17,411,000
13,626,000
Gross Profit
48,975,000
48,975,000
43,989,000
41,872,000
35,078,000
Operating Expense
28,754,000
28,754,000
41,035,000
23,590,000
21,879,000
Operating Income
20,221,000
20,221,000
2,954,000
18,282,000
13,199,000
Net Non Operating Interest Income Expense
-856,000
-856,000
-781,000
-805,000
-770,000
Other Income Expense
571,000
571,000
-284,000
-1,033,000
1,450,000
Pretax Income
19,936,000
19,936,000
1,889,000
16,444,000
13,879,000
Tax Provision
2,803,000
2,803,000
1,512,000
1,918,000
1,521,000
Net Income Common Stockholders
17,117,000
17,117,000
365,000
14,519,000
13,049,000
Diluted NI Available to Com Stockholders
17,117,000
17,117,000
365,000
14,519,000
13,049,000
Basic EPS
67.67
67.60
1.40
57.30
51.60
Diluted EPS
67.40
67.40
1.40
57.10
51.40
Basic Average Shares
252,963.57
253,200
260,714.29
253,200
253,000
Diluted Average Shares
254,100
254,100
260,714.29
254,200
253,800
Total Expenses
43,947,000
43,947,000
57,161,000
41,001,000
35,505,000
Net Income from Continuing & Discontinued Operation
17,117,000
17,117,000
365,000
14,519,000
13,049,000
Normalized Income
17,565,398
17,565,398
861,910
16,278,819
12,174,617.41
Interest Income
415,000
415,000
365,000
157,000
36,000
Interest Expense
1,271,000
1,271,000
1,146,000
962,000
806,000
Net Interest Income
-856,000
-856,000
-781,000
-805,000
-770,000
EBIT
21,207,000
21,207,000
3,035,000
17,406,000
14,685,000
EBITDA
25,706,000
25,706,000
6,907,000
21,315,000
17,899,000
Reconciled Cost of Revenue
15,193,000
15,193,000
16,126,000
17,411,000
13,626,000
Reconciled Depreciation
4,499,000
4,499,000
3,872,000
3,909,000
3,214,000
Net Income from Continuing Operation Net Minority Interest
17,117,000
17,117,000
365,000
14,519,000
13,049,000
Total Unusual Items Excluding Goodwill
-522,000
-522,000
-629,000
-1,993,000
982,000
Total Unusual Items
-522,000
-522,000
-629,000
-1,993,000
982,000
Normalized EBITDA
26,228,000
26,228,000
7,536,000
23,308,000
16,917,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-73,602
-73,602
-132,090
-233,181
107,617.41
12/31/2021 - 12/27/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

BRM.MU Bristol-Myers Squibb Co
56.83
+3.29%
 
AZN.BA AstraZeneca PLC
46,250.00
+0.60%
 
AMGN.MX Amgen Inc.
6,032.00
0.00%
 
ABBV34.SA AbbVie Inc.
76.22
+2.32%
 
AMGN.BA Amgen Inc.
12,500.00
+0.81%
 
GILD.BA Gilead Sciences, Inc.
35,000.00
+2.26%
 
YPHA.F Astellas Pharma Inc.
9.05
-1.09%
 
BIIB.BA Biogen Inc.
13,125.00
0.00%
 
0Q1N.IL Pfizer Inc.
25.95
-0.76%
 
OZTA.SG Grifols SA
10.43
+0.29%